MedTrace Logo

Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide

NCT00283621 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2018-11-07

No results posted yet for this study

Summary

To determine the percentage of patients and number of cycles in which a packed red blood cell transfusion was administered due to anemia and in which antibiotics were administered due to neutropenic fever.

Conditions

  • Sarcoma

Interventions

DRUG

Aranesp (darbepoetin alfa)

DRUG

Neulasta (pegfilgrastim)

DRUG

Adriamycin

DRUG

Ifosfamide

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Saroj Vadhan-Raj, M.D. · UT MDAnderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-06-02
Primary Completion
2006-04-12
Completion
2006-04-12

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00283621 on ClinicalTrials.gov